On March 27, 2015, a federal judge in the U.S. District Court for the District of New Jersey invalidated three patents that Dr. Reddy’s and other generic companies were accused of infringing. Dr. Reddy’s was represented by members of Cantor Colburn’s pharmaceutical litigation team.